Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA

J. W. Sam, S. Takahashi, I. Lippai, J. Peisach, Denis L. Rousseau

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

The binding of the iron complex of the antineoplastic glycopeptide bleomycin A2 (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the β-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281- 1294) of DNA recognition by activated bleomycin, HOO-Fe(III)BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.

Original languageEnglish (US)
Pages (from-to)16090-16097
Number of pages8
JournalJournal of Biological Chemistry
Volume273
Issue number26
DOIs
StatePublished - Jun 26 1998

Fingerprint

Metals
DNA
Pharmaceutical Preparations
Bleomycin
Oligonucleotides
Paramagnetic resonance
Iron
Glycopeptides
Raman Spectrum Analysis
Coordination Complexes
Amides
Antineoplastic Agents
Raman spectroscopy
iron bleomycin
Raman scattering
Phosphates
tri(deoxycytidylic acid-deoxyguanylic acid)
Ligands
pyrimidine
calf thymus DNA

ASJC Scopus subject areas

  • Biochemistry

Cite this

Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA. / Sam, J. W.; Takahashi, S.; Lippai, I.; Peisach, J.; Rousseau, Denis L.

In: Journal of Biological Chemistry, Vol. 273, No. 26, 26.06.1998, p. 16090-16097.

Research output: Contribution to journalArticle

Sam, J. W. ; Takahashi, S. ; Lippai, I. ; Peisach, J. ; Rousseau, Denis L. / Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA. In: Journal of Biological Chemistry. 1998 ; Vol. 273, No. 26. pp. 16090-16097.
@article{633096fe3c1a436f8282ae5010d094f7,
title = "Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA",
abstract = "The binding of the iron complex of the antineoplastic glycopeptide bleomycin A2 (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the β-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281- 1294) of DNA recognition by activated bleomycin, HOO-Fe(III)BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.",
author = "Sam, {J. W.} and S. Takahashi and I. Lippai and J. Peisach and Rousseau, {Denis L.}",
year = "1998",
month = "6",
day = "26",
doi = "10.1074/jbc.273.26.16090",
language = "English (US)",
volume = "273",
pages = "16090--16097",
journal = "Journal of Biological Chemistry",
issn = "0021-9258",
publisher = "American Society for Biochemistry and Molecular Biology Inc.",
number = "26",

}

TY - JOUR

T1 - Sequence-specific changes in the metal site of ferric bleomycin induced by the binding of DNA

AU - Sam, J. W.

AU - Takahashi, S.

AU - Lippai, I.

AU - Peisach, J.

AU - Rousseau, Denis L.

PY - 1998/6/26

Y1 - 1998/6/26

N2 - The binding of the iron complex of the antineoplastic glycopeptide bleomycin A2 (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the β-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281- 1294) of DNA recognition by activated bleomycin, HOO-Fe(III)BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.

AB - The binding of the iron complex of the antineoplastic glycopeptide bleomycin A2 (Fe-BLM) to calf thymus DNA and the self-complementary oligonucleotides d(CGCGCG) and d(ATATAT) has been studied using optical, EPR, and resonance Raman spectroscopies. An increase in the intensity of the bands at 365 and 384 nm is observed in the optical spectrum of Fe(III)-BLM when the drug binds to either oligonucleotide. However, in the presence of phosphate, this increase is observed only with d(CGCGCG) and not with d(ATATAT). In addition, the g(max) feature in the EPR spectrum of low spin Fe(III)-BLM is narrowed in a way suggesting a reduction of possible conformers that the drug can achieve when it is bound to d(CGCGCG) or to calf thymus DNA but not when bound to d(ATATAT). When Fe(III)-BLM is bound to d(CGCGCG), changes in the resonance Raman spectrum of the metal drug complex suggest conformational changes in three of the ligands to iron: the β-hydroxyhistidyl amide, the pyrimidine, and the axial hydroxide. In addition, the Fe-OH band undergoes narrowing, again consistent, with the reduction of conformers of the drug. No such resonance Raman changes are observed upon binding to d(ATATAT). The changes in the pyrimidine modes upon binding d(CGCGCG) to the drug are consistent with a recently proposed model (Wu, W., Vanderwall, D. E., Turner, C. J., Kozarich, J. W., and Stubbe, J. (1996) J. Am. Chem. Soc. 118, 1281- 1294) of DNA recognition by activated bleomycin, HOO-Fe(III)BLM, in which the pyrimidine moiety of the drug is important for the preferential cleavage of 5'-GpPy-3' sequences.

UR - http://www.scopus.com/inward/record.url?scp=0032568950&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032568950&partnerID=8YFLogxK

U2 - 10.1074/jbc.273.26.16090

DO - 10.1074/jbc.273.26.16090

M3 - Article

C2 - 9632661

AN - SCOPUS:0032568950

VL - 273

SP - 16090

EP - 16097

JO - Journal of Biological Chemistry

JF - Journal of Biological Chemistry

SN - 0021-9258

IS - 26

ER -